CPLX4

Across TCGA pan-cancer cohorts, CPLX4 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated CPLX4 data layer compared with 2 for mutation status.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CPLX4 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated CPLX4 expression acts as an unfavorable survival marker, although some lineages such as SKCM and SCLC show a favorable association.

SKCM, KIRP, and STAD are the cancer types where CPLX4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	III,IV	0.621	0.411	<.001	95	view →
KIRP	OS	Quartile	All	0.334	0.744	<.001	86	view →
STAD	OS	Median	II,III,IV	0.487	0.658	.001	79	view →
BLCA	DFS	Median	II,III,IV	0.431	0.570	<.001	56	view →
TGCT	DFS	Quartile	II,III,IV	0.599	1.000	.001	36	view →
KICH	OS	Quartile	All	0.305	0.915	<.001	32	view →
SCLC	OS	Tertile	All	0.821	0.603	.006	30	view →
ACC	OS	Tertile	All	0.382	0.836	.007	27	view →
UVM	OS	Median	III,IV	0.240	0.836	.001	22	view →
ESCA	OS	Median	III,IV	0.624	0.309	.002	20	view →
MESO	DFS	Median	IV	0.178	0.451	.017	9	view →
THCA	OS	Tertile	IV	0.813	1.000	.039	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

CPLX4–SKCM (DFS)

Open the SKCM breakdown →